Abstract
Neuropathic osteoarthropathy is characterised by relatively painless swelling together with extensive damage in bones and joints, predominantly in the feet and ankles. The uncontrolled natural course of the condition leads to gross foot deformity, skin pressure ulceration, spreading infections, and sometimes amputation. Jean-Martin Charcot in 1883 described “Charcot foot” named after him in patients with tabes dorsalis insensitivity. Charcot believed that intrinsic bone weakness was the underlying condition, and was caused by neurogenic deficiencies in bone nutrition. His followers believed such dystrophy to be mediated by sympathetic denervation of the bone vasculature (neurotrophic, or neurovascular theory). Attempts to prove this theory were futile. A neurogenic circulatory disorder potentially relevant to bone nutrition could not be identified. Nowadays, Charcot foot is mostly seen in diabetic neuropathy, which has replaced syphilis as a frequent cause of peripheral nerve dysfunction. Recent studies in the diabetic Charcot foot and bone turnover indicate that the neurotrophic theory is a myth. The assumption of bone resorption due to sympathetic denervation proved to be false - sympathetic activity increases osteoclastic activity and thereby bone loss (sympathomimetic bone resorption). Except for the transient, inflammatory stage of the diabetic Charcot foot, there is no evidence of relevant osteoporosis or demineralisation of the foot skeleton in diabetes.
Key words
Neuroarthropathy - osteoarthropathy - polyneuropathy - osteoporosis - amputation - diabetic foot
References
-
1 Onvlee G J. The Charcot Foot. A critical review and an observational study of a group of 60 patients. Thesis. Medical Faculty, University of Leiden/The Netherlands; 1998
-
2
Horwitz T.
Bone and cartilage debris in the synovial membrane: Its significance in the early diagnosis of neuro-arthropathy.
J Bone Joint Surg.
1948;
30-A
579-588
-
3
Edmonds M E, Watkins P J.
The charcot joint: understanding its natural history leads to new treatment and prevention. Abstract.
Diabetic Med.
1984;
1
144 A
-
4
Sella E J, Barrette C.
Staging of Charcot neuroarthropathy along the medial column of the foot in the diabetic patient.
J Foot Ankle Surg.
1999;
38
34-40
-
5 Frykberg R G. Charcot foot: an update on pathogenesis and management. In: Boulton AJM, Connor H, Cavanagh PR (eds) The foot in Diabetes. 3rd edn. Chichester; John Wiley&Sons 2000: 235-260
-
6
Yu G V, Hudson J R.
Evaluation and treatment of stage 0 Charcot’s neuroarthropathy of the foot and ankle.
J Am Podiatr Med Assoc.
2002;
94
210-220
-
7
Chantelau E.
The perils of procrastination: effects of early versus delayed detection and treatment of incipient Charcot fracture.
Diabetic Med.
2005;
22
1707-1712
-
8 Eichenholtz S N. Charcot joints. Springfield, Illinois; Charles C. Thomas 1966: (quoted by Yu et al. 6, Frykberg 5 and Eckardt et al. 9)
-
9
Eckardt A, Schöllner C, Decking J, Ritter S, Schadmand-Fischer S, Kraus O, Küstner E.
The impact of Syme amputation in surgical treatment of patients with diabetic foot syndrome and Charcot-neuro-osteoarthropathy.
Arch Orthop Trauma Surg.
2004;
124
145-150
-
10
Piaggesi A, Marcocci C, Golia F, Di Gregorio S, Baccetti F, Navalesi R.
Markers for Charcot’s neurogenic osteo-arthropathy in diabetic patients. Abstract.
Diabetes.
2000;
49 (Suppl. 1)
A 32
-
11
Piaggesi A, Rizzo L, Golia F. et al .
Biochemical and ultrasound tests for early diagnosis of active neuro-osteoarthropathy (NOA) of the diabetic foot.
Diabetes Res Clin Pract.
2002;
58
1-9
-
12
Gough A, Abrara H, Li F, Purewal T S, Foster A VM, Watkins P J, Moniz C, Edmonds M E.
Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy.
Diabetic Med.
1997;
14
527-531
-
13
Jude E B, Selby P L, Mawer E B, Burgess J, Boulton A JM.
Inflammatory and bone turnover markers in Charcot arthropathy and osteomyelitis of the feet in diabetic patients. Abstract.
Diabetologia.
2002;
45 (Suppl. 2)
A 341-342
-
14
Meier C, Liu P Y, Handelsman D J, Seibel M J.
Endocrine regulation of bone turnover in men.
Clinical Endocrinology.
2005;
63
603-616
-
15
McGill M, Molyneaux L, Bolton T, Ioannou K, Uren R, Yue D K.
Response of Charcot’s arthropathy to contact casting: assessment by quantitative techniques.
Diabetologia.
2000;
43
481-484
-
16
Eymontt M J, Alavi A, Dalinka M K, Kyle G C.
Bone scinitigraphy in diabetic osteoarthropathy.
Radiology.
1982;
140
475-477
-
17
van Schie C HM, Carrington A L, Abouaesha F, Boulton A JM, Jude E B.
Neuropathic and vascular profiles in diabetic patients with Charcot neuroarthropathy. Abstract.
Diabetes.
2002;
51 (Suppl. 2)
A 543
-
18
Stevens M J, Edmonds M E, Foster A VM, Watkins P J.
Selective neuropathy and preserved vascular responses in the diabetic Charcot foot.
Diabetologia.
1992;
35
148-154
-
19
Shapiro S, Stansberry K B, Hill M A, Meyer M D, McNitt P M, Bhatt B A, Vinik A I.
Normal blood flow response and vasomotion in the diabetic Charcot foot.
J Diab Compl.
1998;
12
147-153
-
20
Charcot J M.
Sur quelques arthropathies qui paraissent dependre d’une lesion du cerveau ou de la moelle epiniere.
Archives de Physiologie normale et pathologique.
1868;
1
161-178
-
21
Charcot J M, Féré C.
Affections osseuses et articulaires du pied chez les tabetiques (Pied tabetique).
Archives de Neurologie.
1883;
6
305-319
-
22
Sanders L J.
The Charcot foot: historical perspective 1827 - 2003.
Diabetes Metab Res Rev.
2004;
20 (Suppl. 1)
S4-S8
-
23
Eloesser L.
On the nature of neuropathic affections of joints.
Ann Surg.
1917;
66
201-207
-
24
O’Connor B L, Palmoski M J, Brandt K D.
Neurogenic acceleration of degenerative joint lesions.
J Bone and Joint Surg.
1985;
67-A
562-572
-
25
LoGerfo F W, Coffman J D.
Vascular and microvascular disease of the foot in diabetes.
New Engl J Med.
1984;
311
1615-1619
-
26
Selby P L.
Osteopenia and diabetes.
Diabetic Med.
1988;
5
423-428
-
27
Johnson L C.
Comment to Williams et al.
Arthritis Rheum.
1966;
9
358-359
-
28
Brower A C, Allman R M.
Pathogenesis of the neurotrophic joint: neurotraumatic vs. neurovascular.
Radiology.
1981;
139
349-354
-
29
Watkins P J, Edmonds M E.
Sympathetic nerve failure in diabetes.
Diabetologia.
1983;
25
73-77
-
30
Boulton A JM.
The diabetic foot: neuropathic in aetiology?.
Diabetic Med.
1990;
7
852-858
-
31
Flynn M D, Edmonds M E, Tooke J E, Watkins P J.
Direct measurement of capillary blood flow in the diabetic neuropathic foot.
Diabetologia.
1988;
31
652-656
-
32
Edmonds M E, Clarke M B, Newton S, Barrett J, Watkins P J.
Increased uptake of radiopharmaceutical in diabetic neuropathy.
Q J Med.
1985;
57
843-855
-
33
Mailis A, Meindok H, Papagapiou M, Pham D.
Alterations of three-phase bone scan after sympathectomy.
Clin J Pain.
1994;
10
146-155
-
34
Togari A.
Adrenergic regulation of bone metabolism: possible involvement of sympatheic innervation of osteoblastic and osteoclastic cells.
Micros Res Tech.
2002;
58
77-84
-
35
Chambers T J.
Regulation of the differentiation and function of osteoclasts.
J Pathol.
2000;
192
4-13
-
36
Udagawa N.
Mechanisms involved in bone resorption.
Biogerontology.
2002;
3
79-83
-
37
Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G.
A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients with chronic hemodialysis.
Am J Kidney Dis.
2001;
37
1247-1252
-
38
Thompson R C, Havel P, Goetz F.
Presumed neurotrophic skeletal disease in diabetic kidney transplant recipients.
JAMA.
1983;
249
1317-1319
-
39
Hadjidakis D J, Lempert U G, Minne H W, Ziegler R.
Bone loss in experimental diabetes. Comparison with the model of inflammation mediated osteopenia.
Horm Metab Res.
1993;
25
77-81
-
40
Herbst S A, Jones K B, Saltzman C L.
Pattern of diabetic neuropathic arthropathy associated with the peripheral bone mineral density.
J Bone Joint Surg (Br).
2004;
86-B
378-383
-
41
Jirkovska A, Kasalicky P, Boucek P, Hosova J, Skibova J.
Calcaneal ultrasonometry in patients with Charcot osteoarthropathy and its relationship with densitometry in the lumbar spine and femoral neck and with markers of bone turnover.
Diabetic Med.
2001;
18
495-500
-
42
Young M J, Marshall A, Adams J E, Selby P L, Boulton A JM.
Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy.
Diabetes Care.
1985;
18
34-38
-
43
Hastings M K, Sinacore D R, Fielder F A, Johnson J E.
Bone mineral density during total contact cast immobilization for a patient with neuropathic (Charcot) arthropathy.
Physical Therapy.
2005;
85
250-256
-
44
Schwartz A V.
Diabetes mellitus: does it affect bone?.
Calcif Tissue Int.
2003;
73
515-519
-
45
Hadjidakis D J, Raptis A E, Mylonakis A, Katsavochristos P, Sfakianakis M, Raptis S A.
The postmenopause in diabetes: bone quality and quantity. Abstract.
Diabetologia.
2001;
44 (Suppl. 1)
A223
-
46
Bouillon R.
Diabetic bone disease.
Calcif Tissue Int.
1991;
49
155-160
-
47
Petrova N L, Foster A VM, Edmonds M E.
Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type-1 and Type-2 diabetes.
Diabetic Med.
2005;
22
756-761
-
48
Arun C A, Moulik P, Thomas J, Vora J P, Fraser W G, Purewal T S.
Does peripheral neuropathy affect bone density of the lower limbs in patients with type-2 diabetes mellitus? Abstract.
Diabetic Med.
2001;
18 (Suppl. 2)
72
-
49
Subramanian V, Thomas A, Skowsky R.
Evaluation of serum markers of bone turnover and osteopenic risk factors in Type-2 diabetics with and without peripheral neuropathy. Abstract.
Diabetes.
1999;
48 (Suppl. 1)
A144
-
50
Jeffcoate W, Lima J, Nobrega L.
The Charcot foot.
Diabetic Med.
2000;
17
253-258
-
51
Anonymous . Berliner medicinische Gesellschaft. .
Sitzung vom 17. November 1886 (in German).
Berliner Klinische Wochenschrift.
1886;
23
851-855
-
52
Chantelau E, Richter A, Schmidt-Grigoriadis P, Scherbaum W A.
The diabetic Charcot foot: MRI discloses bone stress injury as trigger mechanism of neuroarthropathy.
Experimental and Clinical Endocrinology and Diabetes.
2006;
114
118-123
-
53
Petrova N, Donaldson N, Bates M, Foster A VM, Edmonds M E.
In Charcot osteoarthropathy early offloading prevents bone mineral density falls not only in the Charcot foot but in the contralateral non-Charcot-foot. Abstract.
Diabetic Med.
2005;
22 (Suppl. 2)
92
-
54
Edmonds M E, Petrova N, Elias D.
The earliest magnetic resonance imaging sign of mid-foot Charcot osteoarthropathy is oedema of the subchondral (subarticular) bone marrow which needs prompt therapeutic offloading. Abstract.
Diabetic Med.
2005;
22 (Suppl. 2)
93
-
55
Pinar H, Akseki D, Kovanlikaya I, Arac S, Bozkurt M.
Bone bruises detected by magnetic resonance imaging following lateral ankle sprains.
Knee Surg, Sports Traumatol, Arthroscopy.
1997;
5
113-117
-
56
Luetters C M, Keegan T HM, Sidney S, Quesenberry C P, Prill M, Sternfeld B, Kelsey J.
Risk factors for foot fracture among individuals aged 45 years and older.
Osteoporosis Int.
2004;
15
957-963
-
57
Boddenberg U.
Healing time of foot an ankle fractures in patients with diabetes mellitus: literature review and report on own cases.
Zentralbl Chir.
2004;
129
453-459
-
58
Jones K B, Maiers-Yelden K A, Marsh J L, Zimmermann M B, Estin M, Saltzmann C L.
Ankle fractures in patients with diabetes mellitus.
J Bone Joint Surg.
2005;
87-B
489-495
-
59
Chantelau E, Richter A, Ghassem-Zadeh N, Poll L W.
“Silent” bone stress injuries in the feet of diabetic patients with polyneuropathy - a report on 12 cases.
Arch Orthop Trauma Surg.
2006;
126 (in press)
-
60
Forst T, Pfützner A, Kann P. et al .
Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus.
Diabetic Med.
1995;
12
874-879
-
61
Rix M, Andreassen H, Eskildsen P.
Impact of peripheral neuropathy on bone density in patients with type-1 diabetes.
Diabetes Care.
1999;
22
827-831
-
62
Patrick A W, Collier A, Nicoll J J, Pye D W, Young R J, Clarke B F.
Bone mass in the foot and axial skeleton in diabetic patients with peripheral neuropathy. Abstract.
Diabetologia.
1990;
33 (Suppl. 1)
A 168
-
63
Robertson D D, Mueller M J, Smith K E, Commean P K, Pilgram T, Johnson J E.
Structural changes in the forefoot of individuals with diabetes and a prior plantar ulcer.
J Bone J Surg.
2002;
84-A
1395-1404
-
64
Petrova N L, Edmonds M E.
Osteopenia in chronic Charcot osteoarthropathy-differences in Type-1 and Type-2 diabetic patients. Abstract.
Diabetologia.
2002;
45 (Suppl. 2)
A341
-
65
Cundy T F, Edmonds M E, Watkins P J.
Osteopenia and metatarsal fractures in diabetic neuropathy.
Diabetic Med.
1985;
2
461-464
-
66
Krishnan S TM, Quattrini C, Jeriyoska M, Malik R, Rayman G.
Role of small fibre neuropathy in wound healing in type-2 diabetes. Abstract.
Diabetic Med.
2006;
23 (Suppl. 2)
69
Prof. Dr. E. Chantelau
Department of Endocrinology, Diabetes and Rheumatology ·
Heinrich-Heine-Universität · Postfach 10 10 07 · 40001 Düsseldorf · Germany
Phone: +49 (211) 811-8749 ·
Fax: +49 (211) 811-7860
Email: Lobnig@med.uni-duesseldorf.de
